MDT — Medtronic plc

Medtronic (MDT) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $9 billion, up 6.6% reported and 5.5% organic, exceeding expectations.
• Adjusted EPS: $1.36, an 8% increase, $0.05 above guidance.
• Adjusted Operating Margin: 24.1%, down 20 basis points year-over-year, but up 50 basis points sequentially.
• Adjusted Gross Margin: 65.9%, up 70 basis points year-over-year.
• R&D Investment: 8.4% of revenue, increased by 8.9%, outpacing revenue growth.
• SG&A: 32.7% of revenue, up 20 basis points year-over-year.

2. Strategic Updates and Business Highlights

• Growth Drivers: Significant contributions from the cardiac ablation business, particularly the PFA franchise, which grew 71% and is expected to double revenue soon.
• New Product Launches: Successful launches of Simplicity for hypertension and AltaViva for incontinence, with positive early indicators in physician training and consumer interest.
• Market Positioning: Medtronic is focusing on scaling manufacturing and investing in operational capabilities to support growth in key areas.
• Portfolio Management: Continued focus on tuck-in M&A and strategic portfolio adjustments to enhance growth.

3. Forward Guidance and Outlook

• Revenue Growth Guidance: Raised to approximately 5.5% for fiscal 2026, with expectations for continued acceleration in the back half of the year.
• EPS Guidance: Increased to a range of $5.62 to $5.66 for fiscal 2026.
• Third Quarter Expectations: Anticipated revenue growth of approximately 5.5%, with a stronger fourth quarter expected.
• Long-term Outlook: High single-digit EPS growth anticipated for fiscal year 2027, driven by accelerating revenue growth and improved operating margins.

4. Bad News, Challenges, or Points of Concern

• Declines in Certain Areas: Notable declines in cryo revenue (40%) and challenges in the specialty therapies segment, which had flat results.
• Tariff Impact: Expected to have a negative impact on gross margins, with approximately $185 million in tariffs affecting the income statement.
• Market Pressures: Ongoing volume-based procurement in China and competitive pressures in the cardiovascular space could pose risks.

5. Notable Q&A Insights

• Simplicity NCD: The final Medicare National Coverage Determination (NCD) is better than anticipated, allowing broader access and reducing patient pathway barriers.
• PFA Growth: Strong demand and physician interest in the PFA franchise are driving market share gains, with expectations of continued acceleration.
• TAVR Market: Anticipated deceleration in TAVR growth in Q3, with a rebound expected in Q4 due to historical patterns.
• Investment Strategy: Emphasis on reinvesting in growth areas, particularly in R&D and sales/marketing, while maintaining operational efficiency to improve margins.

Overall, Medtronic reported strong financial results and raised its guidance, driven by robust growth in key segments, despite facing challenges in certain areas and external market pressures. The company remains focused on strategic investments and portfolio management to sustain growth momentum.